LOS ANGELES, April 20, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that three aldoxorubicin clinical trials have been accepted for poster presentations during the American Society of Clinical Oncology (ASCO) Annual Meeting being held at McCormick Place in Chicago, Illinois, from June, 3-7, 2016. The three clinical trials to be presented are:
- Title: Phase 2 study of aldoxorubicin in relapsed glioblastoma
Date/Time: June 4, 2016 1:00pm-5:00pm
Poster Session: Central Nervous System Tumors; Abstract 2027 - Title: Phase 1b study of aldoxorubicin + gemcitabine in metastatic solid tumors
Date/Time: June 5, 2016 8:00am-11:30am
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics; Abstract: 2523 - Title: Treatment of HIV-associated Kaposi's sarcoma with aldoxorubicin
Date/Time: June 6, 2016 8:00am-11:30am
Poster Session: Sarcoma; Abstract: 11038
"Presenting the results from these three clinical trials at the ASCO Annual Meeting demonstrates the broad potential for aldoxorubicin and should raise awareness among oncologists," said Daniel Levitt, M.D., Ph.D., CytRx's EVP and Chief Medical Officer. "Based on its unique ability to selectively bind serum albumin and preferentially release drug at the tumor site, aldoxorubicin has now shown clinical anti-cancer activity in several tumor types including our lead indication of advanced soft tissue sarcomas for which we expect top-line data in June from our pivotal Phase 3 trial."
Aldoxorubicin is CytRx's lead anti-cancer drug candidate in clinical development utilizing its LADRTM (Linker Activated Drug Release) technology. A global, pivotal Phase 3 trial in patients with relapsed or refractory soft tissue sarcomas has fully enrolled and top-line results for the primary endpoint of progression-free survival are expected in June 2016. The trial is being conducted under a Special Protocol Assessment granted by the FDA. In addition, CytRx is conducting a randomized Phase 2b clinical trial in patients with second-line small cell lung cancer comparing aldoxorubicin topotecan. CytRx has completed enrollment of a Phase 2 trial with aldoxorubicin for patients with relapsed glioblastoma and continues to follow patients for survival. CytRx also conducted a Phase 2 trial with low doses of aldoxorubicin in patients with HIV-related Kaposi's sarcoma. Aldoxorubicin is currently being tested in two Phase 1b trials in combination with other chemotherapies. The first trial is in combination with gemcitabine for metastatic solid tumors, and the second trial is in combination with ifosfamide as a first-line treatment for patients with soft tissue and bone sarcomas.
About Aldoxorubicin
The widely used chemotherapeutic agent doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m2. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to circulating albumin, the most plentiful protein in the bloodstream. Protein-hungry tumors concentrate albumin, thus increasing the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released. This allows for greater doses (3 ½ to 4 times) of doxorubicin to be administered while reducing its toxic side effects. In studies thus far there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 2,000 mg/m2.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin, and DK049, a novel drug conjugate which is expected to enter clinical trials in 2016. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx's clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform, the outcome, timing or results of CytRx's clinical testing of aldoxorubicin, the risk that any future pre-clinical or human testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds, risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3 clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development and Investor Relations
(310) 826-5648, ext. 304
dhaen@cytrx.com
Investor Relations:
Alexander Capital, LP
(855) 288-ALEX (2539)
cytrx@alexandercapitallp.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytrx-to-present-updated-aldoxorubicin-clinical-trial-data-at-the-american-society-of-clinical-oncology-annual-meeting-in-june-2016-300254251.html
SOURCE CytRx Corporation
